title: Primary chemotherapy in operable breast carcinoma comparing CMF (cyclophosphamide, methotrexate, 5-fluorouracil) with an anthracycline-containing regimen: short-term responses translated into long-term outcomes.
abstract: BACKGROUND
  The role of anthracyclines has been extensively studied in adjuvant chemotherapy, but much less in the primary chemotherapy of early breast carcinoma. This study, comparing CMF (cyclophosphamide, methotrexate, 5-fluorouracil) with the rotational anthracycline-containing regimen CMFEV (CMF plus epirubicin and vincristine) administered as primary chemotherapy, demonstrated a significant increase in clinical complete response in premenopausal women. We report the long-term results.
  
  
  METHODS
  Two hundred and eleven patients with stage I or II palpable breast carcinoma and a tumour diameter of >2.5 cm were randomised to receive CMF or CMFEV for four cycles before surgery. After surgery, the patients in both arms received adjuvant CMF for three cycles.
  
  
  RESULTS
  In the study population as a whole, there was a non-significant 20% reduction in mortality and relapse rates in the CMFEV arm. However, the effect of the experimental regimen was only found in premenopausal patients, especially in terms of relapse-free survival (P=0.07) and locoregional relapse-free survival (P=0.0009), thus mirroring the effect on response rates. After 10 years, the proportions of premenopausal patients free from locoregional relapse as a first event in the CMF and CMFEV groups were 68% and 97%, respectively. No relevant differences were found in postmenopausal patients.
  
  
  CONCLUSIONS
  The overall results of this study showed that the greater activity of the experimental anthracycline-containing combination over CMF as primary chemotherapy in premenopausal patients translated into long-term effects in the same subgroup.
authors.affiliation: Medical Oncology Division, Azienda Ospedaliera Universitaria of Parma, Italy. giorgio.cocconi@tin.it
authors.forename: G
authors.initials: G
authors.lastname: Cocconi
authors.forename: B
authors.initials: B
authors.lastname: Di Blasio
authors.forename: C
authors.initials: C
authors.lastname: Boni
authors.forename: G
authors.initials: G
authors.lastname: Bisagni
authors.forename: E
authors.initials: E
authors.lastname: Rondini
authors.forename: M A
authors.initials: MA
authors.lastname: Bella
authors.forename: F
authors.initials: F
authors.lastname: Leonardi
authors.forename: L
authors.initials: L
authors.lastname: Savoldi
authors.forename: C
authors.initials: C
authors.lastname: Vallisneri
authors.forename: R
authors.initials: R
authors.lastname: Camisa
authors.forename: P
authors.initials: P
authors.lastname: Bruzzi
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use; D018572:Disease-Free Survival; D015251:Epirubicin / Q000008:administration & dosage*; D005472:Fluorouracil / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage*
chemical_list: D015251:Epirubicin; D014750:Vincristine; D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate